You searched for cancer - Page 2 of 469

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 11, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Posted by Medivizor on Jun 11, 2023 in Lung cancer | 0 comments

In a nutshell This evaluated the long-term outcomes of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). The data showed that nivolumab plus ipilimumab increased the long-term overall survival versus chemotherapy in these patients. Some background NSCLC is the most...

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Posted by Medivizor on May 28, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to...

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Posted by Medivizor on May 28, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the occurrence and baseline risk factors of cancer occurrence in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) or tumor necrosis factor inhibitors (TNFis). The data showed a higher risk of cancer development with tofacitinib treatment compared to TNFis in these patients. Some...

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Posted by Medivizor on May 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple-negative breast cancer (TNBC). This study concluded that the combination of taxanes and chemotherapy is effective with manageable side effects in these patients. Some background TNBC is a subtype of BC that tests...

Evaluating the effectiveness of physical exercise programs in breast cancer survivors on health-related quality of life, physical fitness, and body composition

Posted by Medivizor on Apr 30, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of physical exercise (PE) programs in breast cancer (BC) survivors on health-related quality of life (HRQoL), physical fitness, and body composition. The study concluded that PE programs do have a positive impact on BC survivors’ HRQoL, physical fitness, and body composition. Some background...

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Apr 30, 2023 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by Medivizor on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by Medivizor on Apr 30, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by Medivizor on Apr 30, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Posted by Medivizor on Apr 23, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of degarelix (Firmagon) with or without apalutamide (Erleada) before radical prostatectomy (RP; prostate surgery) in patients with high-risk prostate cancer (PC). The data showed that degarelix plus apalutamide significantly improved the pathological response in these patients. Some background...

Evaluating whether there is an association between fertility treatments and the risk of breast cancer in women with a family history of breast cancer or with BRCA mutations.

Posted by Medivizor on Apr 23, 2023 in Infertility | 0 comments

In a nutshell This study evaluated whether fertility treatments increase the risk of breast cancer (BC) in women with a family history of BC or with BRCA mutations. The data showed that fertility treatments did not significantly increase the risk of BC in these women. Some background Treatment for infertility has become common, as people delay...

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Evaluating the effectiveness of physical exercise programs in breast cancer survivors on health-related quality of life, physical fitness, and body composition

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Evaluating whether there is an association between fertility treatments and the risk of breast cancer in women with a family history of breast cancer or with BRCA mutations.

Categories

Recent Posts

Archives

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email